Moxifloxacin induces aortic aneurysm and dissection by increasing osteopontin in mice

Koshun Inada1, Mitsuhisa Koga2, Ayano Yamada2

  • 1Department of Pharmaceutical Care and Health Sciences, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1 Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan.

Insights

Fluoroquinolone antibiotics like moxifloxacin may increase the risk of aortic aneurysm and dissection (AAD). This study shows moxifloxacin can induce AAD in mice by affecting key proteins in the aortic wall.

Area of Science:

  • Cardiovascular Biology
  • Pharmacology
  • Vascular Medicine

Background:

  • Fluoroquinolones are widely prescribed antibiotics.
  • Antibiotic use, particularly fluoroquinolones, is linked to an increased risk of aortic aneurysm and dissection (AAD).
  • The precise mechanisms by which fluoroquinolones contribute to AAD are not fully understood.

Purpose of the Study:

  • To investigate the role of moxifloxacin, a common fluoroquinolone, in the development of AAD.
  • To elucidate the molecular mechanisms underlying moxifloxacin-induced AAD in a mouse model.

Main Methods:

  • A moderate-severity AAD mouse model was established using a high-fat diet and angiotensin II infusion.
  • Mice were subsequently treated with varying doses of moxifloxacin or a vehicle control.
  • Histological staining (H&E, EVG), immunohistochemistry, and Western blot analysis were employed to assess aortic tissue.

Main Results:

  • Moxifloxacin administration induced AAD and elastin degradation in mouse aortic tissues.
  • High-dose moxifloxacin decreased the expression of smooth muscle protein 22α, a marker for vascular smooth muscle cell contractile phenotype.
  • Moxifloxacin increased the expression of osteopontin and matrix metalloproteinase-2 in aortic tissues.

Conclusions:

  • Moxifloxacin may promote the onset of AAD and aortic wall weakening.
  • The mechanism involves increased expression of osteopontin and matrix metalloproteinase-2, alongside decreased expression of smooth muscle protein 22α.
  • These findings highlight a potential risk associated with fluoroquinolone use in susceptible individuals.

Related Concept Videos